Completed PHASE1 INTERVENTIONAL 2-arm NCT02840279

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects

Sponsor: Tetra Discovery Partners

Conditions Alzheimer's Disease

Interventions BPN14770 Placebo

Updated 6 times since 2017 Last updated: Jan 17, 2017 Started: Jun 30, 2016 Primary completion: Nov 30, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02840279, this PHASE1 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Tetra Discovery Partners, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tetra Discovery Partners

Data source: Tetra Discovery Partners

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kalamazoo, United States